221 related articles for article (PubMed ID: 18097341)
41. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.
Taylor PC
Curr Opin Pharmacol; 2010 Jun; 10(3):308-15. PubMed ID: 20172761
[TBL] [Abstract][Full Text] [Related]
42. Immunomodulatory properties of macrolides: overview and historical perspective.
Rubin BK
Am J Med; 2004 Nov; 117 Suppl 9A():2S-4S. PubMed ID: 15586557
[No Abstract] [Full Text] [Related]
43. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.
Vega-Ramos J; Roquilly A; Asehnoune K; Villadangos JA
Curr Opin Pharmacol; 2014 Aug; 17():64-70. PubMed ID: 25128781
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the immunomodulatory properties in mice and in vitro anti-inflammatory activity of cycloartane type saponins from Astragalus species.
Nalbantsoy A; Nesil T; Yılmaz-Dilsiz O; Aksu G; Khan S; Bedir E
J Ethnopharmacol; 2012 Jan; 139(2):574-81. PubMed ID: 22155389
[TBL] [Abstract][Full Text] [Related]
45. Macrolides and airway inflammation in children.
Shinkai M; Rubin BK
Paediatr Respir Rev; 2005 Sep; 6(3):227-35. PubMed ID: 16153572
[TBL] [Abstract][Full Text] [Related]
46. [Mechanisms of therapeutic action of aloe].
Anuszewska EL
Wiad Lek; 2015; 68(2):168-72. PubMed ID: 26181152
[TBL] [Abstract][Full Text] [Related]
47. Brevenal, a Marine Natural Product, is Anti-Inflammatory and an Immunomodulator of Macrophage and Lung Epithelial Cells.
Keeler DM; Grandal MK; McCall JR
Mar Drugs; 2019 Mar; 17(3):. PubMed ID: 30897777
[TBL] [Abstract][Full Text] [Related]
48. [Molecular approach for development of new medicaments for chronic infections treatment].
Zigangirova NA; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):103-9. PubMed ID: 17882840
[TBL] [Abstract][Full Text] [Related]
49. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis.
Mencarelli A; Distrutti E; Renga B; Cipriani S; Palladino G; Booth C; Tudor G; Guse JH; Hahn U; Burnet M; Fiorucci S
Eur J Pharmacol; 2011 Aug; 665(1-3):29-39. PubMed ID: 21554873
[TBL] [Abstract][Full Text] [Related]
50. Helminth products as a potential therapeutic strategy for inflammatory diseases.
Soares MF; Araújo CA
Inflamm Allergy Drug Targets; 2008 Jun; 7(2):113-8. PubMed ID: 18691141
[TBL] [Abstract][Full Text] [Related]
51. Identification of chicken cathelicidin-2 core elements involved in antibacterial and immunomodulatory activities.
van Dijk A; Molhoek EM; Veldhuizen EJ; Bokhoven JL; Wagendorp E; Bikker F; Haagsman HP
Mol Immunol; 2009 Aug; 46(13):2465-73. PubMed ID: 19524300
[TBL] [Abstract][Full Text] [Related]
52. Evidence of an anti-inflammatory role for Vasogen's immune modulation therapy.
Nolan Y; Campbell VA; Bolton AE; Lynch MA
Neuroimmunomodulation; 2005; 12(2):113-6. PubMed ID: 15785113
[TBL] [Abstract][Full Text] [Related]
53. Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis.
Cervin A; Wallwork B
Otolaryngol Clin North Am; 2005 Dec; 38(6):1339-50. PubMed ID: 16326189
[TBL] [Abstract][Full Text] [Related]
54. Immunomodulators as an antimicrobial tool.
Pirofski LA; Casadevall A
Curr Opin Microbiol; 2006 Oct; 9(5):489-95. PubMed ID: 16931122
[TBL] [Abstract][Full Text] [Related]
55. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure.
Erickson B; Sperber K; Frishman WH
Cardiol Rev; 2008; 16(6):273-9. PubMed ID: 18923230
[TBL] [Abstract][Full Text] [Related]
56. The use of oral antibiotics in lower-extremity infections.
Joseph WS; Lefrock J
Clin Podiatr Med Surg; 1996 Oct; 13(4):683-99. PubMed ID: 8902339
[TBL] [Abstract][Full Text] [Related]
57. [Macrolides. Antiinflammatory and immunomodulator effects. Indication in respiratory diseases].
Sacre Hazouri JA
Rev Alerg Mex; 2006; 53(3):108-22. PubMed ID: 16970113
[TBL] [Abstract][Full Text] [Related]
58. [Effect of contemporary chemotherapeutic drugs on phagocyte activity and the immune response].
Nikitin AV; Navashin PS; Smolkina TV
Antibiot Khimioter; 1996; 41(7-8):49-56. PubMed ID: 8999764
[No Abstract] [Full Text] [Related]
59. Update upon efficacy and safety of TNF-α inhibitors.
Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
[TBL] [Abstract][Full Text] [Related]
60. Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents.
Tsuji F; Murai M; Oki K; Seki I; Ueda K; Inoue H; Nagelkerken L; Sasano M; Aono H
Eur J Pharmacol; 2010 Feb; 627(1-3):332-9. PubMed ID: 19878665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
